Application‑based Liquiritin segmentation reveals four primary end‑use categories: pharmaceutical, nutraceutical, cosmetics, and food & beverage. The pharmaceutical segment, driven by Liquiritin’s anti‑inflammatory and hepatoprotective properties, commands the largest share at approximately 45% of market revenue, reflecting extensive clinical trial pipelines and regulatory approvals. Nutraceutical applications—dietary supplements and functional foods—represent about 30%, capitalizing on consumer demand for natural bioactives with antioxidant benefits. Cosmetic formulations, particularly anti‑aging creams and skin‑brightening agents, occupy roughly 15% of the market, where Liquiritin’s melanin‑inhibiting activity adds formulation value. The food & beverage sector, encompassing flavoring agents and fortified products, accounts for the remaining 10%, limited by dosage constraints and flavor compatibility. These application segments collectively define the Liquiritin market’s growth trajectory, with each contributing distinct demand drivers and margin profiles, underscoring the importance of precise market taxonomy for strategic planning.